利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

50 条记录 (耗时 0.015 秒)

    TRANSGENIC ONCOLYTIC VIRUSES AND USES THEREOF
    1.
    发明申请
    TRANSGENIC ONCOLYTIC VIRUSES AND USES THEREOF 审中-公开
    转基因毒素病毒及其用途

    公开(公告)号：WO2008140621A2

    公开(公告)日：2008-11-20

    申请号：PCT/US2007088630

    申请日：2007-12-21

    申请人： SINAI SCHOOL MEDICINE ,  WOO SAVIO L C ,  EBERT OLIVER ,  GARCIA-SASTRE ADOLFO ,  ALTOMONTE JENNIFER

    发明人： WOO SAVIO L C ,  EBERT OLIVER ,  GARCIA-SASTRE ADOLFO ,  ALTOMONTE JENNIFER

    IPC分类号： C12N7/00

    CPC分类号： A61K38/21 ,  A61K35/766 ,  A61K38/00 ,  C07K14/005 ,  C12N2710/12022 ,  C12N2710/16022 ,  C12N2710/16122 ,  C12N2710/16722 ,  C12N2760/20222 ,  C12N2760/20232 ,  C12N2760/20243 ,  A61K2300/00

    摘要： The present disclosure relates to a recombinant oncolytic virus useful for inhibiting the growth of or killing tumor cells. More specifically, the recombinant oncolytic virus contains a heterologous nucleic acid sequence encoding an inflammation suppressive gene including, but not limited to, natural killer cell inhibitor, a chemokine binding protein, and an NF-?B inhibitor. Alternatively, the recombinant oncolytic virus contains a two or more heterologous nucleic acid sequences encoding one or more inflammation suppressive genes including, but not limited to, natural killer cell inhibitor(s), one or more chemokine binding protein(s), and/or one or more NF-?B inhibitor(s). Optionally, a recombinant oncolytic virus may further comprise one or more heterologous viral internal ribosome entry site (IRES) that is neuronally-silent. Such recombinant oncolytic viruses can be used to treat singular tumors or multi-focal tumors, such as those found in hepatocellular carcinoma or other cancers.

    摘要翻译： 本公开涉及可用于抑制肿瘤细胞生长或杀死肿瘤细胞的重组溶瘤病毒。 更具体地，重组溶瘤病毒含有编码炎症抑制基因的异源核酸序列，包括但不限于天然杀伤细胞抑制剂，趋化因子结合蛋白和NF-κB抑制剂。 或者，重组溶瘤病毒含有编码一种或多种炎症抑制基因的两个或多个异源核酸序列，包括但不限于天然杀伤细胞抑制剂，一种或多种趋化因子结合蛋白和/或 一种或多种NF-κB抑制剂。 任选地，重组溶瘤病毒还可以包含一个或多个神经元沉默的异源病毒内部核糖体进入位点（IRES）。 这种重组溶瘤病毒可用于治疗单细胞肿瘤或多灶性肿瘤，例如在肝细胞癌或其他癌症中发现的肿瘤。

    LIVE RECOMBINANT AVIAN VACCINE USING THE AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS AS VECTOR
    3.
    发明申请
    LIVE RECOMBINANT AVIAN VACCINE USING THE AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS AS VECTOR 审中-公开
    使用AVIAN感染性喉镜病毒病毒作为载体的真实重组AVIAN疫苗

    公开(公告)号：WO98033928A1

    公开(公告)日：1998-08-06

    申请号：PCT/FR1998/000122

    申请日：1998-01-23

    IPC分类号： C12N15/09 ,  A61K39/12 ,  A61K39/215 ,  A61P31/12 ,  C07K14/03 ,  C12N7/00 ,  C12N7/01 ,  C12N15/38 ,  C12N15/869 ,  C12N15/86 ,  A61K35/76

    CPC分类号： C12N15/86 ,  A61K2039/51 ,  C07K14/005 ,  C12N2710/16022 ,  C12N2710/16043 ,  C12N2840/20 ,  Y10S424/816

    摘要： The live recombinant avian vaccine comprises, as vector, an ILTV containing and expressing at least a heterologous nucleotide sequence, said nucleotide sequence being inserted in the insertion locus formed by the internal ribosome entry site (IRES) located between the stop codons of COL D and COL E of ILTV and which, in a particular ILTV strain is defined between nucleotides 3873 and 4260 at SEQ ID NO:1. The heterologous nucleotide sequence can be under the control of a strong eukaryotic promoter, such as CMV-IE promoter, and can be derived from viruses of Newcastle disease, Marek disease, Gumboro disease, infectious bronchitis, chicken anaemia, chicken pneumovirosis. The invention also concerns a multivalent vaccine comprising at least two live vaccines as per the invention and the recombined ILTV virus.

    摘要翻译： 活重组禽疫苗作为载体包含含有并表达至少异源核苷酸序列的ILTV，所述核苷酸序列插入由位于COL D的终止密码子之间的内部核糖体进入位点（IRES）形成的插入位点和 ILTV的COL E，并且其在特定ILTV毒株中在SEQ ID NO：1的核苷酸3873和4260之间定义。 异源核苷酸序列可以在强的真核启动子如CMV-IE启动子的控制之下，并且可以衍生自新城疫病，马立克病，冈比罗病，感染性支气管炎，鸡血症，鸡肺病的病毒。 本发明还涉及包含根据本发明的至少两种活疫苗和重组的ILTV病毒的多价疫苗。

    TRUNCATED GLYCOPROTEIN G OF HERPES SIMPLEX VIRUS 2
    5.
    发明申请
    TRUNCATED GLYCOPROTEIN G OF HERPES SIMPLEX VIRUS 2 审中-公开
    截短的疱疹单纯疱疹病毒G蛋白2

    公开(公告)号：WO2017134061A1

    公开(公告)日：2017-08-10

    申请号：PCT/EP2017/052070

    申请日：2017-01-31

    申请人： GU VENTURES AB

    发明人： LILJEQVIST, Jan-Åke

    IPC分类号： C07K14/005 ,  A61K39/245 ,  G01N33/569 ,  A61K39/00

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/70 ,  C12N2710/16022 ,  C12N2710/16034 ,  C12N2710/16071 ,  G01N33/56994

    摘要： The present invention relates to a protein comprising a truncated version of the HSV- 2 protein mg G-2, said protein comprising: (i) an extracellular region of mg G-2 (EX-mg G-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90 %, 95 %, 96 %, 97 %, 98 % or 99 % sequence identity (%SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3; (ii) a truncated transmembrane region of mg G-2 (t-TMR-mg G-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90 % sequence identity (%SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and (iii) an intracellular region of mg G-2 (IC-mg G-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90 % or 95 % sequence identity (%SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.

    摘要翻译： 本发明涉及包含截短形式的HSV-2蛋白mg G-2的蛋白质，所述蛋白质包含：（i）mg G-2的胞外区（EX-mg G -2）或其截短形式，至少285个氨基酸; 所述胞外区或其截短形式与SEQ ID NO：3中存在的相应长度的肽片段具有至少90％，95％，96％，97％，98％或99％的序列同一性（％SI） （ii）2至15个氨基酸的mg G-2（t-TMR-mg G-2）的截短跨膜区; 所述截短的跨膜区域与存在于SEQ ID NO：6中的相应长度的肽片段具有至少90％的序列同一性（％SI） 和（iii）至少18个氨基酸的mg G-2胞内区（IC-mg G-2）或其截短形式; 所述细胞内区域或其截短形式与存在于SEQ ID NO：8中的相应长度的肽片段具有至少90％或95％的序列同一性（％SI）。